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In prostate cancer, biomarkers may provide additional value above standard clinical and pathology parameters to predict outcome
after specific therapy. The purpose of this study is to evaluate an 80kDa fragment of the cell adhesion molecule e-cadherin as a serum
biomarker. A broad spectrum of prostate cancer serum samples, representing different stages of prostate cancer disease, including
benign prostatic hyperplasia (BPH), localised (Loc PCA) and metastatic prostate cancer (Met PCA), was examined for the cleaved
product. There is a significant difference in the expression level of the 80kDa fragment in the serum of healthy individuals vs patients
with BPH and between BPH vs Loc PCA and Met PCA (Po0.001). Highest expression levels are observed in advanced metastatic
disease. In the cohort of Loc PCA cases, there was no association between the 80kDa serum concentration and clinical parameters.
Interestingly, patients with an 80kDa level of 47.9mgl
 1 at the time of diagnosis have a 55-fold higher risk of biochemical failure after
surgery compared to those with lower levels. This is the first report of the application of an 80kDa fragment of e-cadherin as a serum
biomarker in a broad spectrum of prostate cancer cases. At an optimised cutoff, high expression at the time of diagnosis is associated
with a significantly increased risk of biochemical failure, potentially supporting its use for a tailored follow-up protocol for those patients.
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Prostate-specific antigen (PSA) screening has revolutionised early
detection of prostate cancer. Still, prostate cancer is a leading cause
of male cancer-related deaths in the western world. Men with
clinically localised prostate cancer have excellent chances for
long-term cure. However, treatment options are rare in advanced
disease stage or in case of failure after specific therapy. Therefore,
it is crucial to identify the potentially progressing prostate cancer
at its earliest stage. One way to evaluate patient risk is to use
standard nomograms, which take clinical and pathology para-
meters into account. Nomograms have been developed, for
example, for predicting the 5-year probability of treatment failure
among men with clinically localised prostate cancer treated with
radical prostatectomy (Kattan et al, 1998), and the probability of
successful treatment 5 years after brachytherapy for clinically
localised prostate cancer (Kattan et al, 2001). Ideally, nomograms
would help clinicians to identify progressing tumours after specific
therapy, indicating early adjuvant therapeutic means or at least
supporting a more tailored follow-up regimen. There appears to
be significant opportunity to identify biomarkers to strengthen
currently available nomograms by providing information with
respect to tumour biology at the time of diagnosis (Potter et al,
2001).
The 120kDa full-length e-cadherin is known to be important
for well-functioning cell–cell adhesion and its cleavage has
been linked to the malignant progression of adenocarcinomas in-
cluding prostate cancer (Giroldi and Schalken, 1993; Rios-Doria
et al, 2002). In a recent study, an 80kDa fragment of full-length
e-cadherin has been described as almost exclusively being
observed in the neoplastic aspect of prostate cancer tissue (Kuefer
et al, 2003). This soluble fragment has also been reported as being
measurable in the serum of patients suffering from different types
of adenocarcinoma (Katayama et al, 1994a; Banks et al, 1995;
Gofuku et al, 1998; Velikova et al, 1998; Protheroe et al, 1999; Chan
et al, 2003). In the current study, we report the accumulation of
this 80kDa fragment of e-cadherin in the serum of patients
affected by prostate cancer. Its potential use as a serum marker
with predictive value for prostate cancer progression is elucidated.
MATERIALS AND METHODS
Sample collection
Serum samples were taken from the radical prostatectomy series
and from the Rapid Autopsy Program at the University of
Michigan. The serum was collected as a standard procedure of
all individuals undergoing surgery. In order to study hormone
Received 9 December 2004; revised 15 March 2005; accepted 24 March
2005; published online 3 May 2005
*Correspondence: Dr R Kuefer; E-mail: rainer.kuefer@medizin.uni-ulm.de
4These authors contributed equally to this work
British Journal of Cancer (2005) 92, 2018–2023
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
srefractory prostate cancer, a Rapid Autopsy Protocol was
developed. As a routine procedure, blood is taken from these
patients with far advanced disease on a regular basis till the time of
autopsy. Of all patients, blood samples were taken and immedia-
tely processed and stored at  801C. Clinical and pathology data for
all patients was acquired with approval from the Institutional
Review Board (IRB) at the University of Michigan and maintained
on a secure relational database.
In this retrospective setting, serum samples were grouped
according to following clinical categories in order to examine the
widest range of prostate cancer disease: one group consisted of 13
healthy young volunteers. The second group was represented by 29
patients with benign prostatic hyperplasia (BPH). The third group
consisted of 109 patients with localised prostate cancer (Loc PCA).
Of these patients, serum at the time of diagnosis was available and
none of these patients failed during follow-up after radical
prostatectomy. The fourth group included 21 cases with localised
PCA and biochemical failure after surgery during follow-up. The
last cohort consisted of 16 serum samples of different patients with
generalised metastatic disease (Met PCA). Detailed clinical data of
all patients are given in Table 1.
In this study, Loc PCA is defined as all tumour stages according
to the current TNM classification (T1–T4). Patients with node-
positive disease were not included due to the small number of
cases. Also, patients with other malignancies besides PCA or
chronic inflammatory diseases (Katayama et al, 1994a) were
excluded. None of the patients had neoadjuvant therapy and none
of the patients with localised PCA received other cancer-specific
treatment besides radical prostatectomy.
Serum analysis of the 80kDa e-cadherin fragment
Serum concentrations of the 80kDa fragment were analysed
using the Human E-cadherin EIA Kit from Zymed Laboratories,
San Francisco, USA. In this commercially available kit,
HECD-1 is the e-cadherin-specific antibody. HECD-1 is highly
specific and known to map to the extracellular domain of
e-cadherin, where the 80kDa fragment derives from (Kuefer et al,
2003). In the serum, the soluble 80kDa is the only cleaved
product being seen by the HECD-1 antibody. As first step, a
standard curve was created using the suppliers lyophilised
human e-cadherin. To this standard curve, a curve was fitted to
Table 1 Demographics of all patients who were evaluated for the expression of the 80kDa fragment of e-cadherin in the serum
Cases Mean Median Range
Healthy volunteers (n¼13)
Age (years) 13 26.3 27.0 22.0–32.0
BPH (n¼29)
Age (years) 63.6 63.0 60.0–68.0
Negative biopsies 29
Loc PCA
Nonfailures/failures (n¼109/n¼21)
Age (years) 109/21 59.7/62.0 60.0/61.0 36.0–83.0/54.0–73.0
PSA (ngml
 1) 9.8/11.0 6.7/7.0 0.1–90.8/0.2–43.3
Gland weight (g) 61.7/50.4 53.0/42.0 28.2–131/26.3–94.0
Follow-up (days) 934.2/1659.6 867.0/1706.0 41–2226/171–2706
Tumour stage
1 14/1
2 74/2
3 12/8
4 8/7
Gleason sum
Unknown 3/2
6 45/1
7 56/11
8 2/3
9 3/4
Multifocality
0 26/4
1 83/17
Extraprostatic extension
0 93/6
1 16/15
Surgical margin
0 89/8
1 20/13
Seminal vesicle involvement
0 101/14
1 8/7
Met PCA (n¼16)
Age at diagnosis (years) 16 65.2 68.0 57.0–79.0
Months to death after diagnosis 84.5 70.0 15.0–190.0
Gleason sum at diagnosis
o63
7–8 9
9–10 4
BPH¼benign prostatic hyperplasia; Loc PCA¼localised prostate cancer; Met PCA¼metastatic prostate cancer; PSA¼prostate-specific antigen.
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centrations of the individual serum samples. In this setting, a
cubic model with the formula (1.1305 OD)þ( 0.6712 OD
2)
þ(0.1624 OD
3) was the optimal model to fit the standards
(RSQ¼0.981).
Measurements of samples with an OD X3.0 were repeated using
higher dilutions. The kit was tested for low intrasample and
interplate variability. A representative set of samples was also
tested in a time-course experiment to rule out an association
between time till the samples were processed and the amount of
the cleaved e-cadherin fragment.
Absorbance was measured at 450nm using a standard 96-well
microtiter plate reader. Measurement was carried out in triplicate
for each sample and the mean value was used for statistical
analysis.
Statistical analyses
The OD values were imported into SPSS (SPSS, Chicago, USA)
and transformed into 80kDa serum concentrations according
to the above formula for statistical analysis. The expression
levels of the 80kDa serum fragment were evaluated for all
serum samples (i.e. healthy volunteers, BPH, Loc PCA, Met
PCA) and are graphically presented as error bars with 95%
confidence intervals (CI). A comparison of expression
levels between different cohorts (i.e. BPH vs Loc PCA) was
performed using the Mann–Whitney test, or the Wilcoxon’s
signed-rank test for dependent samples. For the Loc PCA samples,
the 80kDa serum expression was investigated for association with
clinical and pathological parameters (e.g. tumour stage) using
Cramer’s V for categorised values. Cramer’s V represents a
correlation coefficient; the lower (towards 0) the less correlation
is given and the higher the value (towards 1), the more correlation
is present. Kaplan–Meier analysis was performed to estimate
survival. As surrogate end point for survival, biochemical
recurrence during follow-up was chosen, being defined as two
consecutive PSA rises after a nadir of undetectable PSA after
surgery. Univariate, unmatched comparisons of survival were
carried out using the log-rank test. The Wald test was used for
Cox’s hazards regression analysis applying a backward stepwise
elimination of variables in multivariate models. Risk ratios
(relative hazards) were calculated based on the Cox model and
are presented with 95% CI. Values of Po0.05 were considered
significant.
RESULTS
Expression of the 80kDa fragment for different clinical
categories
The serum levels of healthy volunteers (n¼13) was compared to
patients with BPH (n¼29) and patients with Loc PCA (n¼130)
and those with Met PCA (n¼16). Healthy volunteers, BPH, Loc
PCA and Met PCA had a mean 80kDa concentration of 6.27
(standard error (s.e.) 0.31, 95% CI 5.59–6.96), 7.26 (s.e. 0.21, CI
6.82–7.70), 9.46 (s.e. 0.42, CI 8.63–10.29) and 27.49 (s.e. 4.81, CI
17.23–37.75), respectively. Pairwise comparison revealed a statis-
tically significant difference between the serum concentration of
the healthy volunteers and the patients with BPH (Mann–Whitney;
P¼0.023) and between patients with BPH and Loc PCA (Mann–
Whitney; P¼0.011). Interestingly, there was a highly significant
difference between the Loc PCA cases and the serum levels of
the patients with metastatic disease (Po0.001). The mean 80kDa
protein expression level for each category is presented in Figure 1,
demonstrating a cascade from healthy volunteers oBPHoLoc
PCAoMet PCA.
Expression of the 80kDa fragment for patients with Loc
PCA
Association of the 80kDa expression with clinical and patho-
logical parameters As the 80kDa fragment has been found
to be associated with aggressive clinical course in bladder,
gastric and colorectal cancer (Griffiths et al, 1996; Gofuku
et al, 1998; Velikova et al, 1998), we looked for potential associa-
tions between clinical or pathological parameters in prostate
cancer. Two statistical approaches were tested: first step was
to create four categories of the 80kDa serum concentration
according to the calculated quartiles; second step was to
categorise using the median of the 80kDa concentration of the
cohort of Loc PCA patients. These categories of the serum
biomarker were compared to the categorised clinical and
pathological parameters. There was no association between
expression of the e-cadherin fragment in the serum and any of
the following parameters: age, race, preoperative PSA, tumour
stage, Gleason score (categorised Gleason sum o7; 7; 47),
multifocality, seminal vesicle involvement, surgical margin, extra-
prostatic extension and weight of prostate gland (Cramer’s V;
values ranged from 0.18 to 0.29)
Comparison of the 80kDa serum level at the time of diagnosis
and at the time of PSA nadir after radical prostatectomy For this
analysis, serum at the time of diagnosis and at the time of nadir
after surgery was available of 21 patients (matched pairs). The
mean 80kDa concentration at the time of diagnosis was 8.27 (s.e.
0.68, 95% CI 6.38–9.54) and 7.32 (s.e. 0.88, CI 5.22–9.13) during
follow-up. The difference was statistically not significant (Wilcox-
on test; P¼0.28).
Comparison of the 80kDa serum expression at the time of diagnosis
and at the time of failure during follow-up For this analysis,
serum at the time of diagnosis and at the time of failure was
available of seven patients (matched pairs) out of 21 patients who
failed. The mean 80kDa concentration at the time of diagnosis was
8.33 (s.e. 0.69, 95% CI 6.65–10.01) and 7.57 (s.e. 0.87, CI 5.44–
9.73) at the time of failure. Statistically there was no significant
difference in expression levels (Wilcoxon test; P¼0.31).
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Figure 1 Detection of the 80kDa fragment of e-cadherin in the serum
of Healthy Individuals (Healthy Ind.), patients with benign prostatic
hyperplasia (BPH), patients with localised prostate cancer (loc PCA) and
with metastatic disease (Met PCA). Mean concentrations including the 95%
confidence interval (CI) are given.
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PCA group (n¼130) The median postsurgery follow-up time was
920.5 days (41–2706 days). The average time to failure was 435.3
days (s.e. 115.5 days). Clinical parameters and the 80kDa fragment
as a serum biomarker were evaluated for their ability to predict
outcome. For statistical analysis, a cutoff for the 80kDa serum level
was set at the calculated median of 7.93mgl
 1 (mean 9.46mgl
 1;
s.e. 0.42; CI 8.63–10.29). Tumour stage, Gleason sum (categorised
o7; 7; 47), extraprostatic extension, seminal vesicle involvement
and surgical margin showed a strong association with outcome
(log rank; Po0.002). Preoperative PSA, age, multifocality of the
prostate cancer and race did not show an association with outcome
(log rank; P40.2). In the multivariate Cox regression analysis,
applying a backward model selection for all the given parameters,
Gleason sum and extraprostatic extension of the cancer had the
best model performance (log rank; P¼0.007). Detailed data of the
Cox proportional-hazard model for all the clinical parameters
including confidence intervals is given in Table 2. As in the case of
the 80kDa e-cadherin fragment, at first glance there was no
association between the serum level and PSA failure (log rank;
P¼0.79, 95% CI 0.48–2.65). Interestingly, when performing a
subanalysis, starting at a follow-up time of 35 months, the 80kDa
level was associated with outcome (log rank; Po0.05). In this
model, the relative risk for PSA failure was 55.1 (s.e. 4.14). The
association between the 80kDa expression and clinical failure is
presented graphically in a Kaplan–Meier curve demonstrating a
significantly higher risk of PSA failure for patients with 80kDa
serum levels 47.9mgl
 1 once a follow-up time of 3 years has
passed (Figure 2).
DISCUSSION
Without doubt, PSA is one of the best tumour markers in
oncology. It was first identified by Hara et al in 1971 in seminal
plasma and some years later in prostate tissue (Wang et al, 1979).
In the last 20 years screening, treatment approaches and follow-up
for prostate cancer have been dramatically influenced by the
widespread usage of PSA. Owing to the high prevalence of
prostate cancer, tumour marker research still is particularly
challenging as PSA is known to have some limitations in its
application especially in the diagnostic window of 4–10ngml
 1
(Partin et al, 1990). In fact, in combination with other clinical
parameters PSA helps to predict locally advanced or metastatic
disease (Sands et al, 1994; Partin et al, 1997; Cagiannos et al, 2003),
whereas limited information is available to predict failure after
specific therapy, possibly guiding high-risk patients into tailored
follow-up protocols (Pound et al, 1999; Kattan et al, 2001). In the
presented study, we ought to analyse a soluble fragment of
e-cadherin for its potential use as a serum biomarker in prostate
cancer disease.
E-cadherin is a cell adhesion molecule playing a major role in
maintaining proper epithelial cell-to-cell structure (Takeichi,
1990). This member of the cadherins, also called uvomorulin, is
a 120kDa transmembrane gylcoprotein. A very early report about
the association between altered cell adhesion and tumour
progression was published by a pathologist almost 60 years ago
(Coman, 1944). After 40 years, reports of e-cadherin cleavage
emerged when Wheelock and Damsky presented the discovery of
a 80kDa species of e-cadherin based on cell culture experiments
(Wheelock et al, 1987). This proteolytic fragment, detectable in the
media of tumour cells, was derived from the amino-terminal end
of e-cadherin and could be reproducibly generated by a series of
stress stimuli such as starving or high calcium loading. This
fragment was thought to act proinvasive due to its ability to
disrupt the cell–cell adhesion of mammary epithelium (Wheelock
et al, 1987; Noe et al, 2001). In several previous studies including
our own, decreased e-cadherin expression either alone or in
combination with other biomarkers has been described as being
associated with prostate cancer progression (Umbas et al, 1992;
Takeichi, 1993; Rubin et al, 2001; Rhodes et al, 2003). We also
reported that increased cleavage of the full-length 120kDa e-
cadherin, leading to 97 and 100kDa fragments, was observed in
neoplastic prostate tissue (Rashid et al, 2001; Rios-Doria et al,
2002). In a recent study, a considerable accumulation of the 80kDa
fragment in the extracellular compartment of metastatic prostate
tissue has been observed (Kuefer et al, 2003). Several potential
mechanisms have been discussed in the literature for being
responsible for the shedding of e-cadherin (Takeichi, 1988;
Katayama et al, 1994b; Banks et al, 1995; Noe et al, 2001; Ryniers
et al, 2002). Still, the underlying pathomechanics need further
investigation as the cleaved product of e-cadherin represents most
likely only a bystander effect. Once these mechanisms, which lead
to the cleaved product, are identified, specific therapy might be
Table 2 Clinical parameters and the concentration of the 80kDa serum
fragment are tested in an univariate and a multivariate regression model for
association with outcome
Variable P-value Hazard ratio 95% CI
Univariate Cox’s proportional-hazard model
Race 0.49 1.16 (0.76–1.79)
Age (years) 0.23 1.03 (0.78–2.14)
Preoperative PSA (ngml
 1) 0.83 1.004 (0.97–1.05)
Gland weight (g) 0.17 0.98 (0.95–1.0)
Gleason sum o0.001 2.49 (1.62–3.84)
Multifocality 0.67 1.27 (0.43–3.78)
Extraprostatic extension o0.001 10.94 (4.22–28.37)
Seminal vesicle involvement 0.002 4.34 (1.74–10.81)
Surgical margin 0.001 4.66 (1.91–11.36)
Tumour stage o0.001 2.67 (1.69–4.22)
80kDa e-cadherin fragment 0.79 1.12 (0.45–2.65)
Multivariate (backward stepwise; Wald)
Gleason sum 0.007 2.16 (1.24–4.25)
Extraprostatic extension 0.007 5.34 (1.60–17.84)
95% CI¼95% confidence interval; PSA¼prostate-specific antigen.
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Figure 2 Association of the soluble 80kDa fragment (cutoff expression
level 7.9mgl
 1) at the time of diagnosis of prostate cancer and biochemical
failure after radical prostatectomy. Patients with localised disease and with
high expression levels prior to surgery have a significantly increased risk of
late biochemical failure (after 3 years) during follow-up.
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marker for successful therapy.
Several studies, all using HECD-1 as the primary antibody for
detection of the 80kDa fragment, have reported the presence of the
80kDA fragment in the serum of patients suffering from intestinal
or bladder cancer.
The amount of detectable soluble 80kDa e-cadherin was
significantly higher in patients with gastric cancer compared to
healthy individuals (Katayama et al, 1994a; Gofuku et al, 1998;
Chan et al, 2001). Indeed, the 80kDa serum levels were more
sensitive for malignancies than well-known tumour markers, the
carcinoembryonic antigen and CA19-9, a ligand of E-selectin
(Gofuku et al, 1998). In a very recent study, the serum
concentrations were an independent predictive factor for long-
term survival in patients with gastric cancer (Chan et al, 2003).
This observation and the fact that the expression levels did not
correlate to clinical parameters such as T-stage is in accordance
with the results described in this study. In contrast to our findings,
for gastric cancer, a quick decline within already 7 days after
surgery was observed (Gofuku et al, 1998). It was stated that a
high concentration in gastric cancer patients predicted palliative
treatment as there was a strong association to metastatic disease
(Chan et al, 2001). Although colon cancer is an intestinal neoplasia
as well, Velikova et al (1998) could not confirm these findings for
colon cancer.
The soluble 80kDa fragment was not only measured in the
serum but also in the urine of patients. In one study, it was
assumed that the 80kDa fragment is excreted into the urine as
increased levels could be measured among patients with different
primaries (Katayama et al, 1994a). In bladder cancer, Banks et al
described the existence of soluble forms of e-cadherin in the urine.
An enhanced shedding and thus increased fraction of e-cadherin
fragments was discussed as a loss of e-cadherin function in
malignant changes of the bladder (Banks et al, 1995). This
observation was put in perspective to the fact that decreased
e-cadherin expression has been shown to be associated with poor
survival in bladder cancer patients (Bringuier et al, 1993; Syrigos
et al, 1995). In a more recent study, the soluble e-cadherin was
included in a protein/creatinine index. This index showed a
significant difference between invasive and noninvasive bladder
cancers. Still, it was concluded that this protein alone most likely
will not be useful for bladder cancer screening (Protheroe et al,
1999). Another study investigated the serum expression at the time
of presentation and found significantly higher expression levels in
patients with high-grade and muscle invasive bladder tumours.
The most interesting finding for bladder cancer, which is in
accordance with the presented results for prostate cancer, was the
fact that patients at risk of early relapse of superficial bladder
tumours had significantly elevated serum levels of soluble e-
cadherin at presentation (Griffiths et al, 1996).
In this study, we demonstrated in a broad spectrum of prostate
cancer disease stages and in comparison to healthy individuals
and benign hyperplasia of the prostate, a very strong association
of the 80kDa fragment in the serum with neoplastic changes of the
gland. The highest expression levels are seen in patients with
advanced hormone refractory metastatic prostate cancer. The
80kDa fragment in this setting was independent of any clinical
parameters, including those related to tumour burden, in the
cohort of clinically localised PCA cases. This observation is
surprising, but may suggest that the 80kDa e-cadherin fragment
reflects biological character of the underlying cancer. The tumour
biology obviously could be directly related to metastatic
potential and thus to late recurrence after specific therapy. This
hypothesis may explain the fact that in this setting patients
with Loc PCA and a high 80kDa serum level at the time of
diagnosis have a considerable high risk of biochemical failure after
surgery starting at a follow-up time of 3 years. To gain further
insight into the underlying pathomechanics and to understand
better why there is no association with tumour burden, a matched
pairs analysis of serum levels of the fragment and e-cadherin
expression in tissue samples might be helpful (Griffiths et al,
1996). Although further work is needed, these observations, in
conjunction with the high serum expression levels in patients
with far advanced lethal PCA, make the authors believe that
the 80kDa expression level has the potential to serve as
biomarker with predictive value. As stated above, a real value for
the urologist most likely could be its application in conjunction
with other well-described parameters after cancer-specific therapy.
It also would be very important to test lymph node-positive
prostate cancer patients for their 80kDa serum levels as these
patients are more likely to fail during follow-up and therefore
would benefit most from a biomarker with predictive value.
Although this study refers to a decent sample size, a limitation
is the low number of events (n¼21), which may explain why PSA
was not a predictor of failure in the cohort of localised PCA cases
in this setting and which results in a limited degree of freedom
in regression models. Consecutively, this serum marker needs to
be approved in a larger and ideally prospective setting. Based on
valid clinical interpretation, it may then help to tailor the follow-up
regimen in patients being at high risk of failure. In upcoming
studies, the end point preferably should not be biochemical failure,
as an association to clinical recurrence or disease-specific death is
most important and needs to be demonstrated. As there was no
change in the serum levels between time of diagnosis and serum
levels after surgery, the 80kDa fragment may also serve as a
marker for patients undergoing other therapeutic means for
localised PCA.
The management of a patient with prostate cancer requires that
prognostic information is available for defining an optimised
treatment plan. The presented results are promising that the
80kDa fragment of e-cadherin can be approved as a serum
biomarker for prostate cancer, being detectable at early stages of
disease before specific therapy is initiated and potentially
providing additional prognostic information besides clinical and
pathological data.
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